Welcome to our dedicated page for Aquestive Therapeutics news (Ticker: AQST), a resource for investors and traders seeking the latest updates and insights on Aquestive Therapeutics stock.
Aquestive Therapeutics, Inc. develops and manufactures specialty pharmaceutical products using proprietary oral-film and drug-delivery technologies. News about AQST centers on the company’s proprietary pipeline, including Anaphylm™ (dibutepinephrine) sublingual film for Type I allergic reactions, including anaphylaxis, and AQST-108, an epinephrine prodrug topical gel being explored for dermatological conditions such as alopecia areata.
Recurring updates also cover FDA interactions and NDA communications for Anaphylm, pharmacokinetic and human-factor study topics, quarterly financial results, licensee and CDMO manufacturing activity, investor presentations, equity inducement grants, and legal, compliance, and board-governance changes.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Aquestive Therapeutics, Inc. (NASDAQ: AQST) has announced its participation in two upcoming investor conferences. The management team will conduct a fireside chat at the JMP Life Sciences Conference on May 15, 2023, at 12:00 pm ET, and will also be available for investor meetings. Additionally, they will be present for investor meetings at A.G.P.'s Virtual Healthcare Conference on May 23, 2023. A webcast of the JMP conference chat will be accessible on the Company's website for 30 days post-event. Aquestive Therapeutics focuses on developing innovative orally administered medications to enhance patient care and has a robust pipeline targeting central nervous system disorders and severe allergic reactions. The Company has several licensed products globally and collaborates with pharmaceutical firms using its proprietary technologies.
Aquestive Therapeutics has announced that the FDA has conditionally accepted the proprietary name Anaphylm™ for its investigational product AQST-109, a sublingual film designed to treat severe allergic reactions, including anaphylaxis. This name, which connects to anaphylaxis and emphasizes its film form, was developed through extensive market research, including healthcare professional feedback. With an estimated 49 million Americans at risk of anaphylaxis, the company aims to improve patient access and usage of its product. Anaphylm's acceptance is contingent upon FDA approval of AQST-109. The product is designed to be portable and easy to use, representing a significant advancement in anaphylaxis treatment.